U.s. fda approves supplemental new drug application for takeda's iclusig® (ponatinib) for adult patients with resistant or intolerant chronic-phase cml

Cambridge, mass. & osaka, japan--(business wire)--takeda pharmaceutical company limited (tse:4502/nyse:tak) today announced that the u.s. food and drug administration (fda) has approved the supplemental new drug application (snda) for iclusig® (ponatinib) for adult patients with chronic-phase (cp) chronic myeloid leukemia (cml) with resistance or intolerance to at least two prior kinase inhibitors. the updated label includes an optimized, response-based iclusig dosing regimen in cp-cml with a d
TAK Ratings Summary
TAK Quant Ranking